Perbak Capital Partners’s Cardinal Health CAH Stock Holding History

Perbak Capital Partners’s Portfolio CAH Stock Details CAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,682	Closed	-$264K	–	233
2025 Q3	$264K	Buy	+1,682	New	+$260K	0.05%	274

Other funds holding CAH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Perbak Capital Partners's CAH Position: Q4 2025 in Review

Perbak Capital Partners sold out of Cardinal Health (CAH) in Q4 2025, closing a stake of 1,682 shares — an estimated $264K sold.

Perbak Capital Partners first reported a position in CAH in Q3 2025 and held it in 1 quarter. The position peaked at $264K in Q3 2025. 1,412 funds tracked by Wall St. Rank hold CAH as of Q4 2025.

Perbak Capital Partners reported no remaining Cardinal Health position as of Q4 2025 after selling out during the quarter.
Perbak Capital Partners sold 1,682 Cardinal Health shares in Q4 2025, an estimated $264K.
Perbak Capital Partners first reported a position in Cardinal Health in Q3 2025 and held it in 1 quarter.
Perbak Capital Partners's Cardinal Health position peaked at $264K in Q3 2025.
1,412 funds tracked by Wall St. Rank held Cardinal Health as of Q4 2025.

Based on Perbak Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.